Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
Larimar’s rolling BLA submission and long-term nomlabofusp data strengthen the case for a potential disease-modifying Friedreich’s ataxia therapy.
Pharma & Biotech
Why Taysha’s Rett syndrome data could become a major gene therapy test case
Find out how Taysha’s TSHA-102 Rett syndrome update could shape gene therapy development, BLA planning and future disease-modifying care.
Pharma & Biotech
Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
Pharma & Biotech
Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar
Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.